BIA welcomes UK ratification of the UPC Agreement

27 April 2018
patent_trademark_big

The UK Minister for Intellectual Property, Sam Gyimah MP, on Thursday (April 26) confirmed that the UK has ratified the Unified Patent Court Agreement (UPCA).

Responding to the announcement, Steve Bates, chief executive of the BioIndustry Association (BIA) comments: “Being able to protect intellectual property is vital for life science companies and is often the key value in emerging bioscience companies. We welcome the announcement that the UK has ratified the UPC Agreement to create a single system for the registration, prosecution and enforcement of patents across much of Europe.

"This will provide the option for businesses to save time and money, which will be of particular benefit for SMEs [small- and medium-sized enterprises], as they will be able to register their patents across the participating countries at reduced cost and enforce them through a centralised court system rather than multiple local courts. The Central Division of the Court with responsibility for life sciences cases is due to be based in London, further cementing the UK’s position as a primary destination for investment. The involvement of the UK judiciary with their significant expertise will also be a major advantage to the new system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical